Skip to search formSkip to main contentSkip to account menu

BB-10010

Known as: BB 10010, BB10010 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

MonokinesSmall Inducible Cytokine A3cytokine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy.
The aim of this study was to determine whether administration of BB-10010, a synthetic stem cell inhibitor, would allow more… 
2000
2000
Chemical modification of a variant of human MIP-1alpha; implications for dimer structure.
A sequence variant of human MIP-1alpha, in which Asp26 has been replaced by Al alpha, has been chemically modified by the… 
1999
1999
BB-10010, an analogue of macrophage inflammatory protein-1 alpha, reduces proliferation in murine small-intestinal crypts.
BACKGROUND The small-intestinal epithelium, a rapidly proliferating tissue, is highly sensitive to cycle-specific agents such as… 
1998
1998
A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.
BB-10010 is a variant of the human form of macrophage inflammatory protein-1alpha (MIP-1alpha), which has been shown in mice to… 
1997
1997
A randomized phase II study of BB‐10010: a variant of human macrophage inflammatory protein‐1α for patients receiving high‐dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer
Macrophage inflammatory protein‐1α (MIP‐1α) is a chemokine that can inhibit the cell cycle progression of both primitive… 
1997
1997
A case study and use of sedimentation equilibrium analytical ultracentrifugation as a tool for biopharmaceutical development
Abstract Analytical ultracentrifugation (AUC) has re-emerged as a powerful technique for protein characterisation. We report the… 
1997
1997
A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast…
Macrophage inflammatory protein-1alpha (MIP-1alpha) is a chemokine that can inhibit the cell cycle progression of both primitive… 
1997
1997
The effects of human macrophage inflammatory protein-1 alpha and its genetically modified variant, BB10010, on phagocyte function.
BB-10010 is a genetically modified form of human macrophage inflammatory protein-1 alpha (MIP-1 alpha) with a single amino acid… 
1996
1996
A phase i trial of subcutaneous (SC) BB-10010 in breast. Cancer patients (PTS) receiving high-dose cyclophosphamide (C)
Highly Cited
1995
Highly Cited
1995
BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.
The stem cell inhibitor, macrophage inflammatory protein-1 alpha (MIP-1 alpha) or LD78, protects multipotent hematopoietic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)